Literature DB >> 2419635

[Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].

H Kiesewetter, F Jung, J Blume, B Bulling, R P Franke.   

Abstract

Rheological therapy, as an immediate treatment in conjunction with physical therapy and the removal of risk factors, plays a significant role in the management of patients with peripheral vascular disease experiencing reduced walking tolerance. An essential element of rheological therapy is hemodilution. Currently, is still uncertain which plasma substitute solution would be the most appropriate in such cases. This study compared the effectiveness of low molecular hydroxyethyl starch to low molecular dextran during a 16-day hemodilution in combination to physical therapy. The clinical improvement observed with both plasma substitute solutions was comparable, yet in view of the cardiac volume overload, dextran demonstrates greater circulatory stress due to the transient pressure increase and more side effects. For this reason, we prefer to administer low or middle molecular hydroxyethyl starch in the dilution treatment of peripheral arterial occlusive disease as a chronic degenerative vascular disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419635     DOI: 10.1007/bf01721578

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  48 in total

1.  THE RENAL EXCRETION OF LOW MOLECULAR WEIGHT DEXTRAN.

Authors:  G ARTRUSON; K GRANATH; L THOREN; G WALLENIUS
Journal:  Acta Chir Scand       Date:  1964-05

2.  THE RENAL CLEARANCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS.

Authors:  G ARTURSON; G WALLENIUS
Journal:  Scand J Clin Lab Invest       Date:  1964       Impact factor: 1.713

3.  Effect of hematocrit on venous return.

Authors:  A C GUYTON; T Q RICHARDSON
Journal:  Circ Res       Date:  1961-01       Impact factor: 17.367

4.  [Methods for the quantitative determination of plasma proteins by immunoprecipitation].

Authors:  W Becker; W Rapp; H G Schwick; K Störiko
Journal:  Z Klin Chem Klin Biochem       Date:  1968-05

5.  [Rheological and clotting investigations after the infusion of HES 200/0.5 and dextran 40. A comparative clinical trial (author's transl)].

Authors:  H Harke; C Pieper; J Meredig; S Rahman; P Rüssler
Journal:  Anaesthesist       Date:  1980-02       Impact factor: 1.041

6.  [The capillary tube plasma viscosimeter. A new apparatus for measuring plasma viscosity].

Authors:  F Jung; H G Roggenkamp; R Schneider; H Kiesewetter
Journal:  Biomed Tech (Berl)       Date:  1983-11       Impact factor: 1.411

7.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

8.  Whole blood viscosity and cerebral blood flow.

Authors:  D J Thomas
Journal:  Stroke       Date:  1982 May-Jun       Impact factor: 7.914

9.  [Randomised study on histaminelike side-effects of 5 common plasmasubstitutes in orthopedic surgery (author's transl)].

Authors:  B Schöning; H Koch
Journal:  Anaesthesist       Date:  1975-12       Impact factor: 1.041

10.  [Reducing of unwanted side effects of modified fluid gelatin by promethazine: controlled clinical trial with orthopaedic patints (author's transl)].

Authors:  B Schöning; H Koch
Journal:  Anaesthesist       Date:  1981-01       Impact factor: 1.041

View more
  2 in total

1.  Haemodilution with dextran 40 and hydroxyethyl starch and its effect on cerebral microcirculation.

Authors:  J Scharf; R von Kummer; T Back; H Reich; G Machens; B Wildemann
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

2.  [Hemodilution in patients with stage IIb peripheral arterial occlusive disease: prospective randomized double-blind comparison of middle-molecular weight hydroxyethyl starch and low-molecular weight dextran solution].

Authors:  H Kiesewetter; F Jung; J Blume; M Gerhards
Journal:  Klin Wochenschr       Date:  1987-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.